These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26290849)

  • 1. Associations Between Hyperuricemia and Chronic Kidney Disease: A Review.
    Prasad Sah OS; Qing YX
    Nephrourol Mon; 2015 May; 7(3):e27233. PubMed ID: 26290849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
    Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
    Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
    Jeon HJ; Oh J; Shin DH
    PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia.
    Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H
    Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum uric acid is independently associated with metabolic syndrome in subjects with and without a low estimated glomerular filtration rate.
    See LC; Kuo CF; Chuang FH; Li HY; Chen YM; Chen HW; Yu KH
    J Rheumatol; 2009 Aug; 36(8):1691-8. PubMed ID: 19531754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uric acid and chronic kidney disease: which is chasing which?
    Johnson RJ; Nakagawa T; Jalal D; Sánchez-Lozada LG; Kang DH; Ritz E
    Nephrol Dial Transplant; 2013 Sep; 28(9):2221-8. PubMed ID: 23543594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3-5.
    Liu X; Wang H; Ma R; Shao L; Zhang W; Jiang W; Luo C; Zhai T; Xu Y
    Clin Exp Nephrol; 2019 Mar; 23(3):362-370. PubMed ID: 30291473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
    Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
    PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary nephropathy associated with hyperuricemia and gout.
    Puig JG; Miranda ME; Mateos FA; Picazo ML; Jiménez ML; Calvin TS; Gil AA
    Arch Intern Med; 1993 Feb; 153(3):357-65. PubMed ID: 8427538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uric acid: a surrogate of insulin resistance in older women.
    Chen LK; Lin MH; Lai HY; Hwang SJ; Chiou ST
    Maturitas; 2008 Jan; 59(1):55-61. PubMed ID: 18082342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider.
    Neri L; Rocca Rey LA; Lentine KL; Hinyard LJ; Pinsky B; Xiao H; Dukes J; Schnitzler MA
    Am J Kidney Dis; 2011 Sep; 58(3):398-408. PubMed ID: 21783292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. J-shaped mortality relationship for uric acid in CKD.
    Suliman ME; Johnson RJ; García-López E; Qureshi AR; Molinaei H; Carrero JJ; Heimbürger O; Bárány P; Axelsson J; Lindholm B; Stenvinkel P
    Am J Kidney Dis; 2006 Nov; 48(5):761-71. PubMed ID: 17059995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
    Ghane Sharbaf F; Assadi F
    Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Electrolyte and acid-base balance disorders in advanced chronic kidney disease].
    Alcázar Arroyo R
    Nefrologia; 2008; 28 Suppl 3():87-93. PubMed ID: 19018744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
    Lee JW; Lee KH
    Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD).
    Sezai A; Soma M; Nakata K; Osaka S; Ishii Y; Yaoita H; Hata H; Shiono M
    J Cardiol; 2015 Oct; 66(4):298-303. PubMed ID: 25649025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to target uric acid to retard CKD progression.
    Kumagai T; Ota T; Tamura Y; Chang WX; Shibata S; Uchida S
    Clin Exp Nephrol; 2017 Apr; 21(2):182-192. PubMed ID: 27339448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.